A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6, when combined with ...

Novo Nordisk's deal with Korro is worth a total of $530 million in research and development (R&D) funding, milestone payments ...

This undated photo provided by Novo Nordisk shows flags bearing the company's logo. (Novo Nordisk via AP) (Uncredited, © Martin Nordmark) A drug approved to treat ...

Market leaders Wegovy from Novo Nordisk and Zepbound from Eli Lilly are both injectable drugs. The two companies are also ...

Terns Pharmaceuticals said its oral obesity drug reduced weight by an average of 4.9% in an early-stage study, joining ...

Nonetheless, it's a big green flag for the biotech's stock that a hungry giant like Novo Nordisk is willing to make such a substantial financial commitment to see what it can do. Similarly ...

Market leaders Wegovy from Novo Nordisk and Zepbound from Eli Lilly ... seeing in particular, no red flags," Mizuho analyst Graig Suvannavejh said about Terns' drug. The company's stock was ...

Intermittent shortages of diabetes drug Ozempic in the European Union that are expected to continue into the final quarter of 2024 because of strong demand will not affect all member states, the ...

Wednesday's edition of Forbes Daily covers TikTok whistleblower claims, the S&P's latest high, Trump's new crypto venture, ...

New data from Novo Nordisk’s phase 3 trial of an oral ... survodutide 4.8 mg versus 4.3% of controls. There was one red flag in the data, however; namely, that around a quarter (24.6%) of ...